Trial Profile
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis
- Focus Pharmacodynamics
- Acronyms DECAMERONE
- 31 Jan 2023 Planned End Date changed from 1 Dec 2010 to 1 Dec 2013.
- 31 Jan 2023 Planned primary completion date changed from 1 Dec 2010 to 1 Dec 2012.
- 31 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment because of failure to include patients.